News & Perspective

Oct 21, 2010

Oct 21, 2010

IDSA studies report on range of flu issues

(CIDRAP News) – Influenza reports presented at the Infectious Diseases Society of America's (IDSA's) annual conference today shed light on a range of topics, including vaccine acceptance among healthcare workers (HCWs) and risk factors for hospitalization in small children.

IDSA members discussed their reports in a press teleconference today from the meeting site in Vancouver, B.C., and the organization also released abstracts online.

Feb 03, 2009

Feb 03, 2009

Experts weigh new H5N1 vaccine strategies

(CIDRAP News) – At an Infectious Diseases Society of America (IDSA) symposium in Washington, DC, today on seasonal and pandemic influenza, a group of experts fielded questions from reporters on some of the new trends and emerging issues, including prepandemic strategies for H5N1 avian influenza vaccines, now that some countries are stockpiling them.

Oct 31, 2008

Oct 31, 2008

Encouraging results reported for injectable flu drug

(CIDRAP News) – BioCryst Pharmaceuticals Inc. reported encouraging results this week in two phase 2 trials of its injectable antiviral drug, peramivir, a potential new treatment for influenza.

Peramivir is a neuraminidase inhibitor, like the licensed antivirals oseltamivir (Tamiflu), which is taken orally, and zanamivir (Relenza), inhaled as a powder.

Nov 15, 2007

Nov 15, 2007

THE PANDEMIC VACCINE PUZZLE Can we vaccinate enough people in time to matter?

Maryn McKennaContributing Writer

(CIDRAP News) – This in-depth article investigates the prospects for development of vaccines to head off the threat of an influenza pandemic posed by the H5N1 avian influenza virus. Its seven parts put advances in vaccine technology in perspective by illuminating the formidable barriers to producing an effective and widely usable vaccine in a short time frame.

Nov 02, 2007

Nov 02, 2007

THE PANDEMIC VACCINE PUZZLE Part 7: Time for a vaccine 'Manhattan Project'?

Editor's note: This is the last in a seven-part series investigating the prospects for development of vaccines to head off the threat of an influenza pandemic posed by the H5N1 avian influenza virus. The series puts promising advances in vaccine technology in perspective by illuminating the formidable barriers to producing large amounts of an effective and widely usable vaccine in a short time.

Sort Results

 

Narrow results

by organization

Newsletter Sign-up

Get CIDRAP news and other free newsletters.

Sign up now»

OUR UNDERWRITERS

Unrestricted financial support provided by

Bentson Foundation 3M Gilead 
Grant support for ASP provided by

  Become an underwriter»